Ulcerative Colitis

The median 12-month risk of clinical relapse in patients with MES 1 was 28.7%, while the estimated annual risk of clinical relapse in patients with a MES 0 was 13.7%.

During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.

New recommendations support the use of probiotics for preterm and low birthweight infants to prevent mortality and necrotizing enterocolitis.

In recent years, ustekinumab and tofacitinib have both been effective in treating ulcerative colitis.

Researchers are continuing to learn how the COVID-19 virus will effect patients with inflammatory bowel disease.

In an international survey, investigators discover women are more likely to suffer from a FGID than men.

Both inflammatory bowel disease and celiac disease share similar risk factors.

Individuals who commonly eat popcorn and drink milk have smaller odds of developing IBD.

In a new study, investigators discover fewer adverse events in patients taking 1 × 109 non-viable B bifidum HI-MIMBb75 cells than for patients taking a placebo.

The adjusted estimate of the burden of hospitalizations related to C. diff infections decreased by 24% between 2011-2017.

In a phase 3 clinical trial, endoscopic endpoints were similar between treatment and placebo groups.

New guidelines suggest patients with moderate to severe ulcerative colitis should be treated with infliximab, tofacitinib, and ustekinumab.

The most common reason IBS patients discontinue treatment is a loss of prescription drug coverage.

Dr. David Rubin discusses what IBD patients can do if they are asked to stop immunosuppressant treatment because of COVID-19.

David T. Rubin, MD, discusses some of the reccomendations for treating patients with IBD during the pandemic.

Patients who do not have the coronavirus should continue IBD therapies, including all scheduled infusions.

Some gastrointestinal symptoms could be exacerbated by contracting the novel coronavirus.

A new deep learning system identifies patients with endoscopic and histologic remission with more than 90% accuracy.

Azathioprine is linked to a slightly higher eGFR for patients with inflammatory bowel disease.